Parallel gene expression profiling of mantle cell lymphoma - How do we transform 'omics data into clinical practice

Current Genomics

Volumn 8, Issue 3, 2007, Pages 171-179

  Ek, Sara ^a   Borrebaeck, Carl A K ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CD20 ANTIGEN; CD52 ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; PREDNISONE; REAGENT; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

B CELL LYMPHOMA; BIOINFORMATICS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DOWNSTREAM PROCESSING; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; INFORMATION PROCESSING; MANTLE CELL LYMPHOMA; PROTEIN ANALYSIS; REVIEW;

EID: 34250211145     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920207780833801     Document Type: Review

References (85)

1. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. and Bloomfield, C.D. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod. Pathol. 2000, 13: 193-207.
2. Shaffer, A.L., Rosenwald, A. and Staudt, L.M. Lymphoid malignancies: the dark side of B-cell differentiation. Nat. Rev. Immunol. 2002, 2: 920-32.
3. Welzel, N., Le, T., Marculescu, R., Mitterbauer, G., Chott, A., Pott, C., Kneba, M., Du, M.Q., Kusec, R., Drach, J., Raderer, M., Mannhalter, C., Lechner, K., Nadel, B. and Jaeger, U. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res. 2001, 61: 1629-36.
4. Pittaluga, S., Tierens, A., Pinyol, M., Campo, E., Delabie, J. and De Wolf-Peeters, C. Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. Br. J. Haematol. 1998, 102: 1301-6.
5. Laszlo, T., Nagy, M., Kelenyi, G. and Matolcsy, A. Immunoglobulin V(H) gene mutational analysis suggests that blastic variant of mantle cell lymphoma derives from different stages of B-cell maturation. Leuk. Res. 2000, 24: 27-31.
6. Thorselius, M., Walsh, S., Eriksson, I., Thunberg, U., Johnson, A., Backlin, C., Enblad, G., Sundstrom, C., Roos, G. and Rosenquist, R. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur. J. Haematol. 2002, 68: 217-24.
7. Camacho, F.I., Algara, P., Rodriguez, A., Ruiz-Ballesteros, E., Mollejo, M., Martinez, N., Martinez-Climent, J.A., Gonzalez, M., Mateo, M., Caleo, A., Sanchez-Beato, M., Menarguez, J., Garcia-Conde, J., Sole, F., Campo, E. and Piris, M.A. Molecular heterogeneity in MCL, defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003, 101: 4042-46.
8. Kienle, D., Krober, A., Katzenberger, T., Ott, G., Leupolt, E., Barth, T.F., Moller, P., Benner, A., Habermann, A., Muller-Hermelink, H.K., Bentz, M., Lichter, P., Dohner, H. and Stilgenbauer, S. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102: 3003-9.
9. Lai, R., Lefresne, S.V., Franko, B., Hui, D., Mirza, I., Mansoor, A., Amin, H.M. and Ma, Y. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Mod. Pathol. 2006, 19: 1498-505.
10. Walsh, S.H., Thorselius, M., Johnson, A., Soderberg, O., Jerkeman, M., Bjorck, E., Eriksson, I., Thunberg, U., Landgren, O., Ehinger, M., Lofvenberg, E., Wallman, K., Enblad, G., Sander, B., Porwit-MacDonald, A., Dictor, M., Olofsson, T., Sundstrom, C., Roos, G. and Rosenquist, R. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003, 101: 4047-54.
11. Weller, S., Faili, A., Garcia, C., Braun, M.C., Le Deist, F.F., de Saint Basile, G.G., Hermine, O., Fischer, A., Reynaud, C.A. and Weill, J.C. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc. Natl. Acad. Sci. USA 2001, 98: 1166-70.
12. Matsumoto, M., Lo, S.F., Carruthers, C.J., Min, J., Mariathasan, S., Huang, G., Plas, D.R., Martin, S.M., Geha, R.S., Nahm, M.H. and Chaplin, D.D. Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice. Nature 1996, 382: 462-6.
13. Ek, S., Hogerkorp, C.M., Dictor, M., Ehinger, M. and Borrebaeck, C.A.K. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer. Res. 2002, 62: 4398-405.
14. He, X., Goronzy, J.J., Zhong, W., Xie, C. and Weyand, C.M. VH3-21 B cells escape from a state of tolerance in rheumatoid arthritis and secrete rheumatoid factor. Mol. Med. 1995, 1: 768-80.
15. Stacey, D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells, Curr. Opin. Cell. Biol. 2003, 15: 158-63.
16. Donnellan, R. and Chetty, R. Cyclin D1 and human neoplasia. Mol. Pathol. 1998, 51: 1-7.
17. Tsujimoto, Y., Yunis, J., Onorato-Showe, L., Erikson, J., Nowell, P.C. and Croce, C.M. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984, 224: 1403-6.
18. Lovec, H., Grzeschiczek, A., Kowalski, M.B. and Moroy, T. Cyclin D1/ bc1-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 1994, 13: 3487-95.
19. Yatabe, Y., Suzuki, R., Tobinai, K., Matsuno, Y., Ichinohasama, R., Okamoto, M., Yamaguchi, M., Tamaru, J., Uike, N., Hashimoto, Y., Morishima, Y., Suchi, T., Seto, M. and Nakamura, S. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000, 95: 2253-61.
20. Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Muller-Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J. and Staudt, L.M. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3: 185-97.
21. Kurtin, P.J. Mantle cell lymphoma. Adv. Anat. Pathol. 1998, 5: 376-98.
22. Zucca, E., Stein, H. and Coiffier, B. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). Ann. Oncol. 1994, 5: 507-11.
23. Swerdlow, S.H. and Williams, M.E. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum. Pathol. 2002, 33: 7-20.
24. Raty, R., Franssila, K., Jansson, S.E., Joensuu, H., Wartiovaara-Kautto, U. and Elonen, E. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. Eur. J. Cancer 2003, 39: 321-9.
25. Matolcsy, A. High-grade transformation of low-grade non-Hodgkin's tymphomas: mechanisms of tumor progression. Leuk. Lymphoma 1999, 34: 251-9.
26. Muller-Hermelink, H.K., Zettl, A., Pfeifer, W. and Ott, G. Pathology of lymphoma progression. Histopathology 2001, 38: 285-306.
27. Lardelli, P., Bookman, M.A., Sundeen, J., Longo, D.L. and Jaffe, E.S. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am. J. Surg. Pathol. 1990, 14: 752-63.
28. Raty, R., Franssila, K., Joensuu, H., Teerenhovi, L. and Elonen, E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur. J. Haematol. 2002, 69: 11-20.
29. Norton, A.J., Matthews, J., Pappa, V., Shamash, J., Love, S., Rohatiner, A.Z. and Lister, T.A. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann. Oncol. 1995, 6: 249-56.
30. Weisenburger, D.D., Vose, J.M., Greiner, T.C., Lynch, J.C., Chan, W.C., Bierman, P.J., Dave, B.J., Sanger, W.G. and Armitage, J.O. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am. J. Hematol. 2000, 64: 190-6.
31. Porcu, P. and Nichols, C.R. Evaluation and management of the "new" lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. Curr. Probl. Cancer 1998, 22: 283-368.
32. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. and Shipp, M.A. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 2002, 20: 1288-94.
33. Boye, J., Elter, T. and Engert, A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 2003, 14: 520-35.
34. Hiddemann, W. and Dreyling, M. Mantle cell lymphoma: therapeutic strategies are different from CLL. Curr. Treat. Options Oncol. 2003, 4: 219-26.
35. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. and Hiddemann, W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 2005, 23: 1984-92.
36. Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C., Schmits, R., Metzner, B., Truemper, L., Reiser, M., Steinhauer, H., Boiron, J.M., Boogaerts, M.A., Aldaoud, A., Silingardi, V., Kluin-Nelemans, H.C., Hasford, J., Parwaresch, R., Unterhalt, M. and Hiddemann, W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105: 2677-84.
37. Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.P., Repp, R., Wandt, H., Pott, C., Seymour, J.F., Metzner, B., Hanel, A., Lehmann, T., Hartmann, F., Einsele, H. and Hiddemann, W. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108: 4003-8.
38. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. and Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006, 24: 4867-74.
39. Brody, J. and Advani, R. Treatment of mantle cell lymphoma: current approach and future directions. Crit. Rev. Oncol. Hematol. 2006, 58: 257-65.
40. Zelenetz, A.D. Mantle cell lymphoma: an update on management. Ann. Oncol. 2006, 17 Suppl 4: iv12-4.
41. Goy, A. New directions in the treatment of mantle cell lymphoma: an overview. Clin. Lymphoma Myeloma 2006, 7 Suppl 1: S24-32.
42. Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., Bloomfield, C.D. and Lander, E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286: 531-7.
43. Rosenwald, A., Alizadeh, A.A., Widhopf, G., Simon, R., Davis, R.E., Yu, X., Yang, L., Pickeral, O.K., Rassenti, L.Z., Powell, J., Botstein, D., Byrd, J.C., Grever, M.R., Cheson, B.D., Chiorazzi, N., Wilson, W.H., Kipps, T.J., Brown, P.O. and Staudt, L.M. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 2001, 194: 1639-47.
44. Harjunpaa, A., Taskinen, M., Nykter, M., Karjalainen-Lindsberg, M.L., Nyman, H., Monni, O., Hemmer, S., Yli-Harja, O., Hautaniemi, S., Meri, S. and Leppa, S. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br. J. Haematol. 2006, 135: 33-42.
45. Fu, K., Weisenburger, D.D., Greiner, T.C., Dave, S., Wright, G., Rosenwald, A., Chiorazzi, M., Iqbal, J., Gesk, S., Siebert, R., De Jong, D., Jaffe, E.S., Wilson, W.H., Delabie, J., Ott, G., Dave, B.J., Sanger, W.G., Smith, L.M., Rimsza, L., Braziel, R.M., Muller-Hermelink, H.K., Campo, E., Gascoyne, R.D., Staudt, L.M. and Chan, W.C. Cyclin D1-negative mantle cell lymphoma: a clinico-pathologic study based on gene expression profiling. Blood 2005, 106: 4315-21.
46. Sander, B., Flygare, J., Porwit-Macdonald, A., Smith, C.I., Emanuelsson, E., Kimby, E., Liden, J. and Christensson, B. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. Int. J. Cancer 2005, 117: 418-30.
47. Islam, T.C., Asplund, A.C., Lindvall, J.M., Nygren, L., Liden, J., Kimby, E., Christensson, B., Smith, C.I. and Sander, B. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 2003, 17: 1880-90.
48. Hofmann, W.K., de Vos, S., Tsukasaki, K., Wachsman, W., Pinkus, G.S., Said, J.W. and Koeffler, H.P. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001, 98: 787-94.
49. Martinez, N., Camacho, F.I., Algara, P., Rodriguez, A., Dopazo, A., Ruiz-Ballesteros, E., Martin, P., Martinez-Climent, J.A., Garcia-Conde, J., Menarguez, J., Solano, F., Mollejo, M. and Piris, M.A. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer. Res. 2003, 63: 8226-32.
50. Ek, S., Bjorck, E., Porwit-MacDonald, A., Nordenskjold, M. and Borrebaeck, C.A.K. Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica 2004, 89: 686-95.
51. Zhu, Y., Hollmen, J., Raty, R., Aalto, Y., Nagy, B., Elonen, E., Kere, J., Mannila, H., Fratissila, K. and Knuutila, S. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br. J. Haematol. 2002, 119: 905-15.
52. Ek, S., Bjorck, E., Hogerkorp, C.M., Nordenskjold, M., Porwit-MacDonald, A. and Borrebaeck, C.A.K. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int. J. Cancer 2006, 118: 2092-7.
53. Greiner, T.C., Dasgupta, C., Ho, V.V., Weisenburger, D.D., Smith, L.M., Lynch, J.C., Vose, J.M., Fu, K., Armitage, J.O., Braziel, R.M., Campo, E., Delabie, J., Gascoyne, R.D., Jaffe, E.S., Muller-Hermelink, H.K., Ott, G., Rosenwald, A., Staudt, L.M., Im, M.Y., Karaman, M.W., Pike, B.L., Chan, W.C. and Hacia, J.G. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc. Natl. Acad. Sci. USA 2006, 103: 2352-7.
54. Rizzatti, E.G., Falcao, R.P., Panepucci, R.A., Proto-Siqueira, R., Anselmo-Lima, W.T., Okamoto, O.K. and Zago, M.A. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br. J. Haematol. 2005, 130: 516-26.
55. Ek, S., Ortega, E. and Borrebaeck, C.A.K. Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma. Leuk. Res. 2005, 29: 205-13.
56. Rinaldi A., Kwee, I., Taborelli, M., Largo, C., Uccella, S., Martin, V., Poretti, G., Gaidano, G., Calabrese, G., Martinelli, G., Baldini, L., Pruneri, G., Capella, C., Zucca, E., Cotter, F.E., Cigudosa, J.C., Catapano, C.V., Tibiletti, M.G. and Bertoni, F. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 2006, 132: 303-16.
57. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J., Jr., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warrike, R., Staudt, L.M. and et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403: 503-11.
58. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. and Staudt, L.M. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J Med. 2002, 346: 1937-47.
59. Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R.D., Chan, W.C., Zhao, T., Haioun, C., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Campo, E., Montserrat, E., Lopez-Guillermo, A., Ott, G., Muller-Hermelink, H.K., Connors, J.M., Braziel, R., Grogan, T.M., Fisher, R.I., Miller, T.P., LeBlanc, M., Chiorazzi, M., Zhao, H., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D. and Staudt, L.M. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp Med. 2003, 198: 851-62.
60. Wright, G., Tan, B., Rosenwald, A., Hurt, E.H., Wiestner, A. and Staudt, L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 2003, 100: 9991-6.
61. De Vos, S., Krug, U., Hofmann, W.K., Pinkus, G.S., Swerdlow, S.H., Wachsman, W., Grogan, T.M., Said, J.W. and Koeffler, H.P. Cell Cycle Alterations in the Blastoid Variant of Mantle Cell Lymphoma (MCL-BV) as Detected by Gene Expression Profiling of Mantle Cell Lymphoma (MCL) and MCL-BV. Diagn. Mol. Pathol. 2003, 12: 35-43.
62. Thieblemont, C., Nasser, V., Felman, P., Leroy, K., Gazzo, S., Callet-Bauchu, E., Loriod, B., Granjeaud, S., Gaulard, P., Haioun, C., Traverse-Glehen, A., Baseggio, L., Bertucci, F., Birnbaum, D., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., Salles, G., Coiffier, B., Berger, F. and Houlgatte, R. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004, 103: 2727-37.
63. Kuppers, R. Prognosis in follicular lymphoma - it's in the microenvironment N Engl. J. Med. 2004, 351: 2152-3.
64. Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., Chan, W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., LeBlanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Connors, J.M., Lansdorp, P.M., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Muller-Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M. and Staudt, L.M. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 2004, 351: 2159-69.
65. Grossbard, M.L. Malignant lymphomas. Atlas of clinical oncology. 2002, London: BC Decker Inc. 135-151.
66. Bea, S., Ribas, M., Hernandez, J.M., Bosch, F., Pinyol, M., Hernandez, L., Garcia, J.L., Flores, T., Gonzalez, M., Lopez-Guillermo, A., Piris, M.A., Cardesa, A., Montserrat, E., Miro, R. and Campo, E. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999, 93: 4365-74.
67. Martinez-Climent, J.A., Vizcarra, E., Sanchez, D., Blesa, D., Marugan, I., Benet, I., Sole, F., Rubio-Moscardo, F., Terol, M.J., Climent, J., Sarsotti, E., Tormo, M., Andreu, E., Salido, M., Ruiz, M.A., Prosper, F., Siebert, R., Dyer, M.J. and Garcia-Conde, J. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001, 98: 3479-82.
68. Monni, O., Oinonen, R., Elonen, E., Franssila, K., Teerenhovi, L., Joensuu, H. and Knuutila, S. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 1998, 21: 298-307.
69. Bentz, M., Plesch, A., Bullinger, L., Stilgenbauer, S., Ott, G., Muller-Hermelink, H.K., Baudis, M., Barth, T.F., Moller, P., Lichter, P. and Dohner, H. t(ll;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2000, 27: 285-94.
70. Schraders, M., Pfundt, R., Straatman, H.M., Janssen, I.M., van Kessel, A.G., Schoenmakers, E.F., van Krieken, J.H. and Groenen, P.J. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 2005, 105: 1686-93.
71. Tagawa, H., Karnan, S., Suzuki, R., Matsuo, K., Zhang, X., Ota, A., Morishima, Y., Nakamura, S. and Seto, M. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005, 24: 1348-58.
72. Rubio-Moscardo, F., Climent, J., Siebert, R., Piris, M.A., Martin-Subero, J.I., Nielander, I., Garcia-Conde, J., Dyer, M.J., Terol, M.J., Pinkel, D. and Martinez-Climent, J.A. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005, 105: 4445-54.
73. de Leeuw, R.J., Davies, J.J., Rosenwald, A., Bebb, G., Gascoyne, R.D., Dyer, M.J., Staudt, L.M., Martinez-Climent, J.A. and Lam, W.L. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum. Mol. Genet. 2004, 13: 1827-37.
74. Kohlhammer, H., Schwaenen, C., Wessendorf, S., Holzmann, K., Kestler, H.A., Kienle, D., Barth, T.F., Moller, P., Ott, G., Kalla, J., Radlwimmer, B., Pscherer, A., Stilgenbauer, S., Dohner, H., Lichter, P. and Bentz, M. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004, 104: 795-801.
75. Wester, K., Asplund, A., Backvall, H., Micke, P., Derveniece, A., Hartmane, I., Malmstrom, P.U. and Ponten, F. Zinc-based fixative improves preservation of genomic DNA and proteins in histoprocessing of human tissues. Lab. Invest. 2003, 83: 889-99.
76. Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C.A., Amini, B., Andersen, E., Andersson, A.C., Angelidou, P., Asplund, A., Asplund, C., Berglund, L., Bergstrom, K., Brumer, H., Cerjan, D., Ekstrom, M., Elobeid, A., Eriksson, C., Fagerberg, L., Falk, R., Fall, J., Forsberg, M., Bjorklund, M.G., Gumbel, K., Halimi, A., Hallin, I., Hamsten, C., Hansson, M., Hedhammar, M., Hercules, G., Kampf, C., Larsson, K., Lindskog, M., Lodewyckx, W., Lund, J., Lundeberg, J., Magnusson, K., Malm, E., Nilsson, P., Odling, J., Oksvold, P., Olsson, I., Oster, E., Ottosson, J., Paavilainen, L., Persson, A., Rimini, R., Rockberg, J., Runeson, M., Sivertsson, A., Skollermo, A., Steen, J., Stenvall, M., Sterky, F., Stromberg, S., Sundberg, M., Tegel, H., Tourle, S., Wahlund, E., Walden, A., Wan, J., Wernerus, H., Westberg, J., Wester, K., Wrethagen, U., Xu, L.L., Hober, S. and Ponten, F. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteomics 2005, 4: 1920-32.
77. Uhlen, M. and Ponten, F. Antibody-based proteomics for human tissue profiling. Mol. Cell Proteomics 2005, 4: 384-93.
78. Ek, S., Andreasson, U., Hober, S., Kampf, C., Ponten, F., Uhlen, M., Merz, H. and Borrebaeck, C.A.K. From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies. Mol. Cell Proteomics 2006, 5: 1072-81.
79. Ghobrial, I.M., McCormick, D.J., Kaufmann, S.H., Leontovich, A.A., Loegering, D.A., Dai, N.T., Krajnik, K.L., Stenson, M.J., Melhem, M.F., Novak, A.J., Ansell, S.M. and Witzig, T.E. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 2005, 105: 3722-30.
80. Marengo, E., Robotti, E., Bobba, M., Liparota, M.C., Rustichelli, C., Zamo, A., Chilosi, M. and Righetti, P.G. Multivariate statistical tools applied to the characterization of the proteomic profiles of two human lymphoma cell lines by two-dimensional gel electrophoresis. Electrophoresis 2006, 27: 484-94.
81. Antonucci, F., Chilosi, M., Parolini, C., Hamdan, M., Astner, H. and Righetti, P.G. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis 2003, 24: 2376-85.
82. Wingren, C. and Borrebaeck, C.A.K. Antibody microarrays: current status and key technological advances. Omics 2006, 10: 411-27.
83. M'Kacher, R., Farace, F., Bennaceur-Griscelli, A., Violot, D., Clausse, B., Dossou, J., Valent, A., Parmentier, C., Ribrag, V., Bosq, J., Carde, P., Turhan, A.G. and Bernheim, A. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet. Cytogenet. 2003, 143: 32-8.
84. Smith, M.R., Joshi, I., Jin, F. and Al-Saleem, T. Murine model for mantle cell lymphoma. Leukemia 2006, 20: 891-3.
85. Gladden, A.B., Woolery, R., Aggarwal, P., Wasik, M.A. and Diehl, J.A. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006, 25: 998-1007.